DK0800536T3 - Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser - Google Patents
Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelserInfo
- Publication number
- DK0800536T3 DK0800536T3 DK95944692T DK95944692T DK0800536T3 DK 0800536 T3 DK0800536 T3 DK 0800536T3 DK 95944692 T DK95944692 T DK 95944692T DK 95944692 T DK95944692 T DK 95944692T DK 0800536 T3 DK0800536 T3 DK 0800536T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- pct
- recombinant
- mediated disorders
- antagonists useful
- Prior art date
Links
- 108010002616 Interleukin-5 Proteins 0.000 title abstract 3
- 102000000743 Interleukin-5 Human genes 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36313194A | 1994-12-23 | 1994-12-23 | |
US08/470,110 US5693323A (en) | 1994-12-23 | 1995-06-06 | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US08/467,420 US5683892A (en) | 1994-12-23 | 1995-06-06 | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
PCT/US1995/017082 WO1996021000A2 (en) | 1994-12-23 | 1995-12-22 | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0800536T3 true DK0800536T3 (da) | 2007-04-02 |
Family
ID=27408594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95944692T DK0800536T3 (da) | 1994-12-23 | 1995-12-22 | Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser |
Country Status (22)
Country | Link |
---|---|
US (1) | US6129913A (da) |
EP (1) | EP0800536B1 (da) |
JP (2) | JP2001523083A (da) |
CN (1) | CN100391977C (da) |
AT (1) | ATE346867T1 (da) |
AU (1) | AU708951B2 (da) |
BR (1) | BR9510499B1 (da) |
CA (1) | CA2208503C (da) |
CZ (1) | CZ297045B6 (da) |
DE (1) | DE69535319T2 (da) |
DK (1) | DK0800536T3 (da) |
ES (1) | ES2277336T3 (da) |
FI (1) | FI119374B (da) |
HK (1) | HK1003651A1 (da) |
HU (1) | HU222992B1 (da) |
LU (1) | LU92912I2 (da) |
MX (1) | MX9704779A (da) |
NL (1) | NL300787I1 (da) |
NO (2) | NO324181B1 (da) |
NZ (1) | NZ301916A (da) |
PL (1) | PL194312B1 (da) |
WO (1) | WO1996021000A2 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5783184A (en) * | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2479927C (en) * | 2002-03-29 | 2013-03-12 | Schering Corporation | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20070219117A1 (en) * | 2003-10-27 | 2007-09-20 | Medvet Science Pty Ltd | Bidentate motif and methods of use |
EP1810690B1 (en) * | 2004-10-28 | 2012-01-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-IL-5 receptor antibody for use in treating endometriosis. |
JP2010526087A (ja) | 2007-04-30 | 2010-07-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗il−5抗体を投与するための方法 |
JP4335286B2 (ja) | 2008-02-08 | 2009-09-30 | ファナック株式会社 | 部品保護機能を備えたロボット制御装置及びロボット制御方法 |
ES2441945T3 (es) | 2008-03-28 | 2014-02-07 | Glaxosmithkline Llc | Métodos de tratamiento |
EA023700B1 (ru) * | 2010-01-28 | 2016-07-29 | Глаксо Груп Лимитед | Cd127-связывающие белки |
CA2824279A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
MA42692A (fr) | 2015-08-24 | 2018-07-04 | Glaxosmithkline Ip No 2 Ltd | Compositions biopharmaceutiques |
CN109195990A (zh) * | 2016-03-30 | 2019-01-11 | Musc研究发展基金会 | 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法 |
RU2758008C2 (ru) | 2016-12-23 | 2021-10-25 | Сефалон, Инк. | Анти-il-5 антитела |
EA201992802A1 (ru) * | 2017-05-26 | 2020-07-10 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Биофармацевтические композиции и связанные с ними способы |
CN111065651B (zh) * | 2017-09-29 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | Il-5抗体、其抗原结合片段及医药用途 |
CN109942706A (zh) * | 2017-12-21 | 2019-06-28 | 三生国健药业(上海)股份有限公司 | 结合人il-5的单克隆抗体、其制备方法和用途 |
US20220010008A1 (en) * | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
WO2020200099A1 (zh) * | 2019-03-29 | 2020-10-08 | 江苏恒瑞医药股份有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
WO1990004979A2 (en) * | 1988-11-03 | 1990-05-17 | Schering Corporation | Method of preventing or reducing eosinophilia |
US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ZA929328B (en) * | 1991-12-02 | 1993-07-20 | Fluor Corp | Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine. |
KR0150060B1 (ko) * | 1992-02-06 | 1998-08-17 | 에릭 에스. 딕커 | 사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현 |
JPH06141885A (ja) * | 1992-11-05 | 1994-05-24 | Chemo Sero Therapeut Res Inst | モノクローナル抗体 |
AU1289795A (en) * | 1993-11-19 | 1995-06-06 | Baylor College Of Medicine | Monoclonal antibodies specific for human interleukin-5 |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US5783184A (en) * | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
WO2001012646A1 (en) * | 1999-08-19 | 2001-02-22 | Smithkline Beecham Corporation | Sialoadhesin factor-1 agonist and antagonist antibodies |
-
1995
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en active IP Right Grant
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
-
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
-
1998
- 1998-04-09 HK HK98103015A patent/HK1003651A1/xx not_active IP Right Cessation
-
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
-
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown
- 2015-12-18 NL NL300787C patent/NL300787I1/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0800536T3 (da) | Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser | |
BR0008688A (pt) | Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 | |
SE9604793D0 (sv) | New polymorphs | |
ES2108120T3 (es) | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. | |
DK0771197T3 (da) | Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander | |
DK0726765T3 (da) | Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel | |
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
YU48528B (sh) | Analozi 5-(1-hidroksi-2-piperidinopropil)-2-(1h,3h)-indolona | |
FI971967A0 (fi) | Dioksomorfoliinien käyttö sisäloisten torjuntaan, uusia dioksomorfiineja ja menetelmä niiden valmistamiseksi | |
YU7797A (sh) | Kombinovana terapija za osteoporozu | |
BR9910180A (pt) | Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico | |
DK0473671T3 (da) | Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel | |
UA48940C2 (uk) | Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень | |
DK0712311T3 (da) | Antiglucocorticoidsteroider til behandling af angstlidelser | |
DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
FI973221A0 (fi) | 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina | |
ATE78162T1 (de) | 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. | |
ES2091039T3 (es) | Nuevos bis-fenil-hexenos. | |
DK0817863T3 (da) | Fremgangsmåde til fremstiling af spirolaxin-methylether |